Chronic Pain in America: Who is at Greatest Risk?

Pain relief with suzetrigine was comparable to that seen with placebo, an issue Vertex plans to address with study design as the drug moves to the pivotal phase 3 trials.

In our latest episode, an obesity medicine physician explains the importance of a comprehensive plan to manage chronic pain in patients with obesity.

The FDA has set a PDUFA date of January 30, 2025 for the investigational oral nonopioid therapy for acute pain, which could be a first-in-class win for Vertex.

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Lynn Webster, MD, past president of the American Academy of Pain Medicine.

Findings from a systematic review and meta-analysis showed 1 in 3 youth with chronic pain were diagnosed with anxiety and 1 in 8 were diagnosed with depression.

One in 9 primary care encounters involved a mental health condition, according to an analysis of over 350 million primary care visits.